Study:
A Phase III Trial of Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin (DCEP) and G-CSF With or Without Thalidomide (NSC #66847) as Salvage Therapy for Patients With Refractory Multiple Myeloma
Rationale:
Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Thalidomide may stop the growth of tumor cells by stopping
blood flow to the tumor. It is not yet known if combination chemotherapy is more effective
with or without thalidomide for multiple myeloma.
Purpose:
Randomized phase III trial to compare the effectiveness of combination chemotherapy
with or without thalidomide in treating patients who have refractory multiple myeloma.
Study Status: Terminated
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Multiple Myeloma |
Biological: filgrastim
Drug: cisplatin
Drug: cyclophosphamide
Drug: dexamethasone
Drug: etoposide
Drug: thalidomide |
Phase 3 |
Verified by
Southwest Oncology Group
June, 2012
Sponsored by: Southwest Oncology Group
Information provided by: Southwest Oncology Group
ClinicalTrials.gov identifier: NCT00005834
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Mohamad A. Hussein, MD., Study Chair